Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.83, $0.28 better than the analyst estimate of $0.55. Revenue for the quarter came in at $164.9 million versus the consensus estimate of $151.42 million.

Emergent BioSolutions sees FY2015 revenue of $510-540 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.